MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals ...

The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the ...

MONROE TOWNSHIP, N.J., & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET ...

The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...

PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan for ...

The FDA has set a PDUFA target action date of March 29, 2026. “The development of LNTH-2501 underscores our commitment to expanding access to high-quality diagnostic solutions in oncology,” said Brian ...

A cyclotron is a complicated device that makes very short-lived radioisotopes. These radioisotopes can be used to manufacture radiopharmaceuticals for positron emission tomography (PET) imaging. PET ...

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class ...

Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western EuropeImprove reliability and accessibility of life-saving ...

Iran has ranked among the world’s top three radiopharmaceutical producers, providing isotopes to domestic centres and ...

The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the ...